Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 205
- Registration Number
- NCT01266564
- Locations
- 🇱🇧
Hotel Dieu de France; Oncology, Beirut, Lebanon
🇱🇧Haykal Hospital, Tripoli, Lebanon
🇱🇧Beirut Governmental University Hospital, Beirut, Lebanon
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
Phase 1
Completed
- Conditions
- Malignant Melanoma
- Interventions
- Drug: RO5185426
- First Posted Date
- 2010-12-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT01264380
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
Phase 2
Completed
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- First Posted Date
- 2010-12-21
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 42
- Registration Number
- NCT01263704
- Locations
- 🇮🇱
ASSAF Harofe; Department of Hematology, Rishon Lezion, Israel
🇮🇱Haemek Medical Center; Hematology Department, Afula, Israel
🇮🇱Hadassah Ein Karem Hospital; Haematology, Jerusalem, Israel
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT01260181
- Locations
- 🇵🇹
Hospital Geral; Servico de Pneumologia, Coimbra, Portugal
🇵🇹IPO de Lisboa; Servico de Pneumologia, Lisboa, Portugal
🇵🇹Hospital de Santa Maria; Servico de Pneumologia, Lisboa, Portugal
A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4
- Registration Number
- NCT01260194
A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]Drug: ribavirin
- First Posted Date
- 2010-12-10
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 395
- Registration Number
- NCT01258101
A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Phase 1
Completed
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Biological: PRM-151Other: Placebo
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 21
- Registration Number
- NCT01254409
- Locations
- 🇺🇸
Duke Clinical Research Unit, Durham, North Carolina, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇳🇱Center for Human Drug Research, Leiden, Netherlands
An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2015-02-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT01254331
A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases
Phase 2
Completed
- Conditions
- Malignant Melanoma
- Interventions
- Drug: RO5185426
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT01253564
- Locations
- 🇨🇭
CHUV; Departement d'Oncologie, Lausanne, Switzerland
🇨🇭Universitätsspital Zürich; Dermatologische Klinik, Zürich, Switzerland
A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis
Phase 4
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: tocilizumab [RoActemra/Actemra]Drug: DMARD
- First Posted Date
- 2010-12-01
- Last Posted Date
- 2014-11-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT01251120
© Copyright 2025. All Rights Reserved by MedPath